STAT2d
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
Hosted on MSN1mon
Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat
Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for its biggest moneymaker, a colon cancer test called Cologuard. Please watch ...
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential
Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...
FiercePharma5d
Exact Sciences debuts first Spanish-language Cologuard ads to drive colon cancer screening in Latino community
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign ...
bovnews2d
Wells Fargo Issues Overweight Rating for Exact Sciences Corp (EXAS) Stock
Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...
Exact Sciences Unusual Options Activity For September 16
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...
Buy Rating Affirmed for Exact Sciences Following Promising CRC Screening Test Data
Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.
Morningstar2d
Exact Sciences Corp EXAS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...